Conbercept ophthalmic injection is an anti-vascular endothelial growth factor (VEGF) drug used for neovascular (wet) age-related macular degeneration (nAMD), choroidal neovascularization (pmCNV) secondary to pathological myopia, or visual impairment secondary to diabetic macular edema (DME).
This product is a VEGF receptor-antibody recombinant fusion protein that can competitively inhibit VEGF binding to receptors and prevent the activation of VEGF family receptors, thereby inhibiting endothelial cell proliferation and angiogenesis.
Let us work together to protect precious health